Evidence map›Paper›PMID 34233659›Full record

ArticleCancer cell international2021

Prognostic signature composed of transcription factors accurately predicts the prognosis of gastric cancer patients.

Liqiang Zhou, Zhiqing Chen, You Wu, Hao Lu, Lin Xin

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Liqiang Zhou *Department of General Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Donghu District, Nanchang, 330006, Jiangxi, China.
Zhiqing Chen *Molecular Medicine Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China.
You WuDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Donghu District, Nanchang, 330006, Jiangxi, China.
Hao LuDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Donghu District, Nanchang, 330006, Jiangxi, China.
Lin XinDepartment of General Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Road, Donghu District, Nanchang, 330006, Jiangxi, China. 351442519007@email.ncu.edu.cn.ORCID http://orcid.org/0000-0001-5958-6155
Nanchang University · CN

Funding

Education Department of Jiangxi Province GJJ180024Innovative Research Group Project of the National Natural Science Foundation of China 81560492Innovative Research Group Project of the National Natural Science Foundation of China 81760549Innovative Research Group Project of the National Natural Science Foundation of China 81872480Natural Science Foundation of Jiangxi Province 20203BBG73056
6 · The paper itself

Abstract

backgroundTranscription factors (TFs) are involved in important molecular biological processes of tumor cells and play an essential role in the occurrence and development of gastric cancer (GC).

methodsCombined The Cancer Genome Atlas Program and Genotype-Tissue Expression database to extract the expression of TFs in GC, analyzed the differences, and weighted gene co-expression network analysis to extract TFs related to GC. The cohort including the training and validation cohort. Univariate Cox, least absolute contraction and selection operator (LASSO) regression, and multivariate Cox analysis was used for screening hub TFs to construct the prognostic signature in the training cohort. The Kaplan-Meier (K-M) and the receiver operating characteristic curve (ROC) was drawn to evaluate the predictive ability of the prognostic signature. A nomogram combining clinical information and prognostic signatures of TFs was constructed and its prediction accuracy was evaluated through various methods. The target genes of the hub TFs was predicted and enrichment analysis was performed to understand its molecular biological mechanism. Clinical samples and public data of GC was collected to verify its expression and prognosis. 5-Ethynyl-2'-deoxyuridine and Acridine Orange/Ethidium Bromide staining, flow cytometry and Western-Blot detection were used to analyze the effects of hub-TF ELK3 on the proliferation and apoptosis of gastric cancer in vitro.

resultsA total of 511 misaligned TFs were obtained and 200 GC-related TFs were exposed from them. After systematic analysis, a prognostic signature composed of 4 TFs (ZNF300, ELK3, SP6, MEF2B) were constructed. The KM and ROC curves demonstrated the good predictive ability in training, verification, and complete cohort. The areas under the ROC curve are respectively 0.737, 0.705, 0.700. The calibration chart verified that the predictive ability of the nomogram constructed by combining the prognostic signature of TFs and clinical information was accurate, with a C-index of 0.714. Enriching the target genes of hub TFs showed that it plays an vital role in tumor progression, and its expression and prognostic verification were consistent with the previous analysis. Among them, ELK3 was proved in vitro, and downregulation of its expression inhibited the proliferation of gastric cancer cells, induced proliferation, and exerted anti-tumor effects.

conclusionsThe 4-TFs prognostic signature accurately predicted the overall survival of GC, and ELK3 may be potential therapeutic targets for GC.

Indexed as

ELK3Gastric cancerNomogramPrognostic signatureTranscription factors

Identifiers

PMID34233659
PMCPMC8261954
OpenAlexW3178469654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.